会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • THIN-FILM SOLAR BATTERY AND METHOD OF MAKING SAME
    • 薄膜太阳能电池及其制造方法
    • US20140290739A1
    • 2014-10-02
    • US14221569
    • 2014-03-21
    • Hiroshi Deguchi
    • Hiroshi Deguchi
    • H01L31/032H01L31/18
    • H01L31/0322H01L31/03923H01L31/0749Y02E10/541Y02P70/521
    • A thin-film solar battery includes a substrate, a first electrode, a photoelectric conversion layer, and a second electrode. The first electrode, the photoelectric conversion layer, and the second electrode are laminated on the substrate. The photoelectric conversion layer has a laminated layer structure which includes at least a p-type layer and an n-type layer. The p-type layer is formed of Cu, In, Ga, and Se, and a composition ratio of Se of the p-type layer is equal to or higher than 40 atomic % and less than 50 atomic %. The n-type layer is a compound of an element of at least one Group selected from Group 2, Group 7, and Group 12, an element of Group 13, and an element of Group 16, and contains at least In as the element of Group 13 and at least S as the element of Group 16.
    • 薄膜太阳能电池包括基板,第一电极,光电转换层和第二电极。 第一电极,光电转换层和第二电极层叠在基板上。 光电转换层具有至少包含p型层和n型层的叠层结构。 p型层由Cu,In,Ga和Se形成,p型层的Se的组成比为40原子%以下且小于50原子%。 n型层是选自组2,组7和组12中的至少一个基团的元素的化合物,第13族的元素和第16族的元素,并且至少含有In作为 第13组,至少S为第16组元素。
    • 3. 发明申请
    • 2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETHOXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENESULFONATE, CRYSTAL OF SAME, CRYSTAL POLYMORPH THEREOF, AND METHODS FOR PRODUCTION THEREOF
    • 2 - [[[2 - [(羟基乙基)氨基] -4-吡啶基]甲基]硫代] -N- [4-(三氟甲基)苯基] -3-吡啶甲酰氧基苯甲酸酯,其晶体,其晶体结构及其方法 生产
    • US20120116088A1
    • 2012-05-10
    • US13384590
    • 2010-07-16
    • Masashi NiwaHiroshi Deguchi
    • Masashi NiwaHiroshi Deguchi
    • C07D401/12
    • C07D213/82A61K31/455C07B2200/13C07C303/32C07C309/29C07D401/12
    • In the course of developing 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration.
    • 在开发2 - [[[2 - [(羟基乙酰基)氨基] -4-吡啶基]甲基]硫基] -N- [4-(三氟甲氧基)苯基] -3-吡啶甲酰胺(化合物A)的过程中, 多个问题:1)化合物A或其盐难以重结晶,储存稳定性根据盐的种类而有很大差异,难以获得具有优异储存稳定性的化合物A的盐; 2)在化合物A的结晶过程中,控制晶体多晶型是非常困难的,3)化合物A(游离体)在重复口服给药时会引起胃中的矿物质沉积。 为了解决这些问题,我们考察了盐的种类,结果发现化合物A的1)苯磺酸盐在1周的初步稳定性试验(严重试验)中不会被光,湿度等因素分解 ),并且其储存稳定性没有问题; 2)选择性地生成化合物A的苯磺酸盐的两种晶体形式的方法,以及3)即使在4周的重复口服给药后也没有观察到在胃中的矿物质沉积 。